Cefuroxime Dali Pharma, 750 mg, powder for solution for injection or infusion (10ml vial) Malta - English - Medicines Authority

cefuroxime dali pharma, 750 mg, powder for solution for injection or infusion (10ml vial)

dali pharma gmbh brehmstrasse 56, 40239, dusseldorf,, germany - powder for solution for infusion or injection - cefuroxime sodium 750 mg - antibacterials for systemic use

Cefuroxime Dali Pharma, 1500 mg, powder for solution for injection or infusion (10ml vial) Malta - English - Medicines Authority

cefuroxime dali pharma, 1500 mg, powder for solution for injection or infusion (10ml vial)

dali pharma gmbh brehmstrasse 56, 40239, dusseldorf,, germany - powder for solution for infusion or injection - cefuroxime sodium 1500 mci - antibacterials for systemic use

Cefuroxime Dali Pharma, 750 mg, powder for solution for injection or infusion (15ml vial) Malta - English - Medicines Authority

cefuroxime dali pharma, 750 mg, powder for solution for injection or infusion (15ml vial)

dali pharma gmbh brehmstrasse 56, 40239, dusseldorf,, germany - powder for solution for infusion or injection - cefuroxime sodium 750 mg - antibacterials for systemic use

Cefuroxime Dali Pharma, 1500 mg, powder for solution for injection or infusion (15ml vial) Malta - English - Medicines Authority

cefuroxime dali pharma, 1500 mg, powder for solution for injection or infusion (15ml vial)

dali pharma gmbh brehmstrasse 56, 40239, dusseldorf,, germany - powder for solution for infusion or injection - ceftriaxone sodium 1500 mg - antibacterials for systemic use

CEFUROXIME SXP cefuroxime (as sodium) 1500 mg powder for  injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

cefuroxime sxp cefuroxime (as sodium) 1500 mg powder for injection vial

southern xp ip pty ltd - cefuroxime sodium, quantity: 1577.7 mg (equivalent: cefuroxime, qty 1500 mg) - injection, powder for - excipient ingredients: - cefuroxime sxp is indicated in adults and children of 40 kg or greater in weight for the prevention of infections associated with certain surgical procedures of the gastrointestinal (including oesophageal), orthopaedic, cardiovascular and gynaecological systems (including caesarean section) (see section 4.4: special warnings and precautions for use and section 5.2: pharmacokinetic properties).,in the prevention of infections in which it is very likely that anaerobic organisms will be encountered, cefuroxime should be administered with additional appropriate antibacterial agents such as metronidazole.,consideration should be given to official guidance on the appropriate use of antibacterial agents, as antibiotic prophylaxis is not required in all gastrointestinal, orthopaedic, cardiovascular and gynaecological procedures or surgeries.,for patients with specific cardiac conditions which predispose them to endocarditis who are undergoing abdominal surgery for which surgical antibiotic prophylaxis is indicated, the prophylaxis regimen should additionally include an antibiotic active against enterococci.,for patients undergoing orthopedic or cardiovascular surgery known to be, or at risk of being, colonised or infected with methicillin-resistant s. aureus (mrsa), add an antibiotic with activity against mrsa, such as vancomycin.,cefuroxime sxp is not indicated in children less than 40 kg in weight.

CEFUROXIME SXP cefuroxime (as sodium) 750 mg powder for  injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

cefuroxime sxp cefuroxime (as sodium) 750 mg powder for injection vial

southern xp ip pty ltd - cefuroxime sodium, quantity: 788.9 mg (equivalent: cefuroxime, qty 750 mg) - injection, powder for - excipient ingredients: - cefuroxime sxp is indicated in adults and children of 40 kg or greater in weight for the prevention of infections associated with certain surgical procedures of the gastrointestinal (including oesophageal), orthopaedic, cardiovascular and gynaecological systems (including caesarean section) (see section 4.4: special warnings and precautions for use and section 5.2: pharmacokinetic properties).,in the prevention of infections in which it is very likely that anaerobic organisms will be encountered, cefuroxime should be administered with additional appropriate antibacterial agents such as metronidazole.,consideration should be given to official guidance on the appropriate use of antibacterial agents, as antibiotic prophylaxis is not required in all gastrointestinal, orthopaedic, cardiovascular and gynaecological procedures or surgeries.,for patients with specific cardiac conditions which predispose them to endocarditis who are undergoing abdominal surgery for which surgical antibiotic prophylaxis is indicated, the prophylaxis regimen should additionally include an antibiotic active against enterococci.,for patients undergoing orthopedic or cardiovascular surgery known to be, or at risk of being, colonised or infected with methicillin-resistant s. aureus (mrsa), add an antibiotic with activity against mrsa, such as vancomycin.,cefuroxime sxp is not indicated in children less than 40 kg in weight.

CEFUROXIME AXETIL- cefuroxime axetil tablet, film coated United States - English - NLM (National Library of Medicine)

cefuroxime axetil- cefuroxime axetil tablet, film coated

preferred pharmaceuticali inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 500 mg - cefuroxime axetil tablets usp are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes . limitations of use cefuroxime axetil tablets usp are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae, haemophilus influenzae (including β-lactamase–producing strains), moraxella catarrhalis (including β-lactamase–producing strains), or streptococcus pyogenes . cefuroxime axetil tablets usp are indicated for the treatment of adult and pediatric patients (13 years and older) with mild-to-moderate acute bacterial maxillary sinusitis caused by susceptible strains of streptococcus pneumoniae or haemophilus influenzae (non- β-lactamase–producing strains only). limitations of use the effectiveness of cefuroxime axetil tablets usp for sinus infections caused by β-la